Inhalation Sciences signs new CRO contract worth 75 KEUR with returning global pharma client
(Stockholm, 22 June 2020) Inhalation Sciences (ISAB) has signed a new CRO (Contract Research) order worth 75 KEUR for a project using its in vitro lung simulation tool DissolvIt[®]. The contract is with a returning CRO client—a noted global pharma company. CEO Manoush Masarrat: “This new order from a returning client underlines the benefits DissolvIt[®] gives inhaled drug developers. The voluminous, precise data DissolvIt[® ]deliver are, quite simply, leading. It’s a world-class solution. This new order confirms it once again.”Contract Research has long been an essential part of ISAB’s